Zentalis Q2 net loss widens on higher R&D costs

Zentalis Pharmaceuticals

06/08/2026 22:36

Overview
Oncology drug developer's Q2 net loss widened as R&D expenses rose on trial milestones
Company completed enrollment in DENALI Part 2a and 2b, advancing accelerated approval strategy for azenosertib
Cash and equivalents totaled $174.6 mln at June 30, 2026, providing runway into late 2027

Outlook
Zentalis expects DENALI Part 2 topline readout in 1H 2027 to support accelerated approval
ASPENOVA Phase 3 confirmatory trial is enrolling to support full approval in US and ex-US markets
Company says cash position is sufficient to fund operations into late 2027

Result Drivers
TRIAL MILESTONES - Increased R&D expenses driven by milestone payment for ASPENOVA Phase 3 trial commencement and higher clinical and manufacturing costs
DENALI ENROLLMENT - Completion of enrollment in DENALI Part 2a and 2b supported advancement of accelerated approval strategy for azenosertib
REGULATORY ENGAGEMENT - Alignment with FDA on dose and study population maintained accelerated approval pathway for azenosertib

Company press release: ID:nGNXdxVyS

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.59
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Zentalis Pharmaceuticals Inc is $7.00, about 41.4% above its August 5 closing price of $4.95

Reuters Recommended Reads
Aug 6 - CG Oncology Q2 net loss widens on higher R&D costs
Aug 6 - ALX Oncology Q2 net loss narrows on lower R&D costs
Aug 6 - US FDA approves Replimune's skin cancer drug after prior rejections 

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)